Tirzepatide, a first-in-class dual GIP/GLP-1 receptor agonist, is generating clinical signals that extend well past its established weight-loss profile. Data from the SYNERGY-NASH trial indicate the drug may resolve active steatohepatitis and reduce hepatic fibrosis in biopsy-confirmed MASH patients — outcomes that lifestyle intervention alone rarely sustains. The mechanisms are plausible and layered: simultaneous GIP and GLP-1 receptor engagement reduces hepatic lipid influx, lowers insulin resistance, and suppresses pro-inflammatory cytokines, attacking three of MASH's core pathological drivers in parallel.
This finding lands at a critical juncture. MASH now affects an estimated 5% of adults globally and is on track to become the leading indication for liver transplantation within a decade. Until resmetirom's recent FDA approval, no pharmacological agent had cleared the regulatory bar for MASH-specific fibrosis reduction. Tirzepatide's incretin-based mechanism is mechanistically distinct from resmetirom's thyroid hormone receptor-beta agonism, raising the prospect of combination strategies.
However, important caveats apply. This is a narrative review — not a randomized controlled trial — and the SYNERGY-NASH data it draws on, while promising, represent relatively short follow-up in selected trial populations. Long-term durability of fibrosis benefit after potential drug discontinuation remains entirely unknown. The liver-specific effect independent of weight loss has not been cleanly isolated. For clinicians managing metabolic liver disease, tirzepatide is a compelling adjunct candidate, but confirmatory phase-3 histological data over 72-plus weeks are essential before repositioning it as a primary MASH therapy.